Volume : 08, Issue : 11, November – 2021
26.LIPID ABNORMALITIES IN NON-DIABETIC, NON-OBESE AND PATIENTS OF HYPERTENSION
Dr Abdur Rahman Abshar
Background: Dyslipidemia and hypertension are among the main contributors to the pathogenesis of coronary artery disease, and their coexistence does not increase the risk, but rather increases it.
OBJECTIVE: The aim of this study was to determine the frequency of dyslipidemia in non-obese, non-diabetic hypertensive patients and to compare it with the same frequency in non-obese, non-diabetic, normotensive patients.
Methods: This case-control study was conducted in the Department of Medicine, Khyber Teaching Hospital Peshawar for six months duration from January 2021 to June 2021. 120 adults of both sexes were included in the study; 40 non-obese, non-diabetic, hypertensive patients and 80 non-obese, non-diabetic, normotensive individuals. Demographic data and eating habits of each subject were recorded using a questionnaire. Fasting lipid profile and blood glucose of all subjects were evaluated. All data were compared between the two groups.
Results: The hypertensive group showed higher total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG), and lower high-density lipoprotein cholesterol (HDL-C) values compared to the hypertensive group. Normo-tensive group. In males only, TC, LDL-C, HDL-C abnormalities and TG were more common in the hypertensive group (odds ratio = 2.96, 2.67, 4.28 and 4.57), respectively. HDL-C abnormality in women was similar in both groups (odds ratio = 1.47).
Conclusion: Hypertensive individuals are more likely to have various lipid abnormalities such as total cholesterol, LDL-C, HDL-C (men), and triglycerides compared to the normotensive population.
Keywords: Non-obese, Non-diabetic, Hypertensive, Dyslipidemia.
Cite This Article:
Please cite this article in press Abdur Rahman Abshar et al, Lipid Abnormalities In Non-Diabetic, Non Obese And Patients Of Hypertension., Indo Am. J. P. Sci, 2021; 08(11).
Number of Downloads : 10
1. Santos AS, Rodrigues AP, Rosa LP, Sarrafzadegan N, Silveira EA. Cardiometabolic risk factors and Framingham Risk Score in severely obese patients: Baseline data from DieTBra trial. Nutrition, Metabolism and Cardiovascular Diseases. 2020 Mar 9;30(3):474-82.
2. Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgraduate medicine. 2017 Nov 17;129(8):811-21.
3. Diwan AG, Kuvalekar AA, Dharamsi S, Vora AM, Nikam VA, Ghadge AA. Correlation of serum adiponectin and leptin levels in obesity and type 2 diabetes mellitus. Indian journal of endocrinology and metabolism. 2018 Jan;22(1):93.
4. Zhang H, Lin S, Gao T, Zhong F, Cai J, Sun Y, Ma A. Association between sarcopenia and metabolic syndrome in middle-aged and older non-obese adults: a systematic review and meta-analysis. Nutrients. 2018 Mar;10(3):364.
5. Opoku S, Gan Y, Fu W, Chen D, Addo-Yobo E, Trofimovitch D, Yue W, Yan F, Wang Z, Lu Z. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. 2019 Dec;19(1):1-5.
6. Kotsis V, Tsioufis K, Antza C, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Redon J, Redon P. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. Journal of hypertension. 2018 Jul 1;36(7):1441-55.
7. Gebreyes YF, Goshu DY, Geletew TK, Argefa TG, Zemedu TG, Lemu KA, Waka FC, Mengesha AB, Degefu FS, Deghebo AD, Wubie HT. Prevalence of high bloodpressure, hyperglycemia, dyslipidemia, metabolic syndrome and their determinants in Ethiopia: Evidences from the National NCDs STEPS Survey, 2015. PloS one. 2018 May 9;13(5):e0194819.
8. Ferrara D, Montecucco F, Dallegri F, Carbone F. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. Journal of cellular physiology. 2019 Dec;234(12):21630-41.
9. Hall JE, Mouton AJ, da Silva AA, Omoto AC, Wang Z, Li X, do Carmo JM. Obesity, kidney dysfunction, and inflammation: Interactions in hypertension. Cardiovascular Research. 2021 Jul 1;117(8):1859-76.
10. Kuwabara M, Kuwabara R, Niwa K, Hisatome I, Smits G, Roncal-Jimenez CA, MacLean PS, Yracheta JM, Ohno M, Lanaspa MA, Johnson RJ. Different risk for hypertension, diabetes, dyslipidemia, and hyperuricemia according to level of body mass index in Japanese and American subjects. Nutrients. 2018 Aug;10(8):1011.
11. Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XX, Chien N. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. The lancet Gastroenterology & hepatology. 2020 Aug 1;5(8):739-52.
12. Naqvi S, Naveed S, Ali Z, Ahmad SM, Khan RA, Raj H, Shariff S, Rupareliya C, Zahra F, Khan S. Correlation between glycated hemoglobin and triglyceride level in type 2 diabetes mellitus. Cureus. 2017 Jun;9(6).
13. Aloud AA, Chinnadurai V, Govindasamy C, Alsaif MA, Al-Numair KS. Galangin, a dietary flavonoid, ameliorates hyperglycaemia and lipid abnormalities in rats with streptozotocin-induced hyperglycaemia. Pharmaceutical biology. 2018 Jan 1;56(1):302-8.
14. Chu DT, Nguyet NT, Dinh TC, Lien NV, Nguyen KH, Ngoc VT, Tao Y, Le DH, Nga VB, Jurgoński A, Tran QH. An update on physical health and economic consequences of overweight and obesity. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018 Nov 1;12(6):1095-100.
15. Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non‐alcoholic fatty liver disease in non‐obese and lean individuals. Journal of Gastroenterology and Hepatology. 2021 Jun;36(6):1497-507.
16. Iqbal J, Al Qarni A, Hawwari A, Alghanem AF, Ahmed G. Metabolic syndrome, dyslipidemia and regulation of lipoprotein metabolism. Current diabetes reviews. 2018 Oct 1;14(5):427-33.
17. Gaiz A, Mosawy S, Colson N, Singh I. Thrombotic and cardiovascular risks in type two diabetes; Role of platelet hyperactivity. Biomedicine & pharmacotherapy. 2017 Oct 1;94:679-86.
18. Yanai H, Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: Mechanisms and perspectives. International journal of molecular sciences. 2019 Jan;20(5):1190.
19. Prakash GT, Das AK, Habeebullah S, Bhat V, Shamanna SB. Maternal and neonatal outcome in mothers with gestational diabetes mellitus. Indian journal of endocrinology and metabolism. 2017 Nov;21(6):854.
20. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019 Mar 1;92:98-107.